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Histamine H3 receptor (H3R) antagonists/inverse agonists possess potential to treat
diverse disease states of the central nervous system (CNS). Cognitive dysfunction and
motor impairments are the hallmark of multifarious neurodegenerative and/or psychiatric
disorders. This review presents the various neurobiological/neurochemical evidences
available so far following H3R antagonists in the pathophysiology of Alzheimer’s disease
(AD), attention-deficit hyperactivity disorder (ADHD), schizophrenia, and drug abuse each
of which is accompanied by deficits of some aspects of cognitive and/or motor functions.
Whether the H3R inverse agonism modulates the neurochemical basis underlying the
disease condition or affects only the cognitive/motor component of the disease process
is discussed with the aim to provide a rationale for their use in diverse disease states that
are interlinked and are accompanied by some common motor, cognitive and attentional
deficits.
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Histamine H3 receptor (H3R) antagonists/inverse agonists have
revealed potential to treat diverse disease states of the cen-
tral nervous system (CNS) including Alzheimer’s disease (AD),
attention-deficit hyperactivity syndrome (ADHD), schizophre-
nia, obesity, pain, epilepsy, narcolepsy, substance abuse, etc.
(Leurs et al., 2011; Passani and Blandina, 2011). The histamine
H3R was first identified in the rat brain (Arrang et al., 1983),
its presence in the human brain was confirmed a few years later
(Arrang et al., 1988); and it was successfully cloned and function-
ally expressed by Lovenberg et al. (1999) following which there
was spurt of activities by several academic groups and pharma-
ceutical companies to develop a flurry of compounds that could
therapeutically modulate the functions of this receptor. Though
there is no direct pathophysiological mechanism linking any dis-
ease condition of the CNSwith histamine, the distinct localization
of H3Rs in the CNS coupled with the fact that it modulates the
release of other neurotransmitters in the brain via its action on
heteroreceptors on non-histaminergic neurons led to evaluation
of its ligands in various brain diseases (Nuutinen and Panula,
2010).
H3R, a G-protein coupled receptor (GPCR, coupled to Gi/o
proteins), is able to signal on its own i.e., without activa-
tion by an agonist, and thus displays constitutive activity. H3R
activation inhibits synthesis of histamine through adenylate
cyclase/protein kinase A and calcium/calmodulin-dependent pro-
tein kinase type II (CaMKII) pathways. In addition, it can
activate phospholipase A2 (PLA2) mediated release of arachi-
donic acid (AA) and phosphoinositol-3-kinase activity result-
ing in activation of the Akt/glycogen synthase kinase (GSK)-3β
axis (Leurs et al., 2005). Evidence linking how these signaling
pathways relate to the efficacy of H3R antagonists in various
disease states is scarce. Though the role of histamine H3Rs as
therapeutic target in brain diseases have been the subject of
many recent reviews, here we have tried to bring together var-
ious neurobiological/neurochemical evidences available so far
following H3R ligands in the pathophysiology of AD, ADHD,
schizophrenia, and drug abuse each of which is accompanied
by deficits of some aspects of cognitive and/or motor func-
tions. Whether the H3R inverse agonism modulates the neu-
rochemical basis underlying the disease condition or affects
only the cognitive/motor component of the disease process is
discussed.
ALZHEIMER’S DISEASE
AD is a chronic and progressive neurodegenerative brain dis-
ease and one of the most prevalent forms of dementia affecting
nearly 20 million people worldwide (Chen et al., 2012). Role of
histamine in AD is well documented. But, owing to variable find-
ings concerning the histamine levels in brain compartments of
AD patients, a direct correlation between histaminergic neuro-
transmission and AD pathology cannot be made and hence the
rationale of using H3R antagonists in the treatment of AD is
rather complex (Fernández-Novoa and Cacabelos, 2001; Brioni
et al., 2011). Few studies by a group of Spanish researchers claim
that histamine levels in AD patients is increased in areas such
as temporal and frontal cortex, basal ganglia, and hippocampus
(Cacabelos et al., 1989) also, together with its metabolites, in the
cerebrospinal fluid (CSF) and serum of AD patients (Cacabelos
et al., 1992; Fernandez-Novoa et al., 1997), although this rise in
histamine level has been vaguely attributed to its non-neuronal
pool i.e., mast cells in the CNS [reviewed by Fernández-Novoa
and Cacabelos (2001)].
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On the contrary to the above findings, several indepen-
dent studies show decline in histamine levels in AD brains.
The tuberomamillary nucleus (TMN) seems to be affected in
AD as occurrence of high density of neurofibrillary tangles
(NFT) surrounding tuberomammillary histaminergic neurons
was observed inAD patients (Saper andGerman, 1987), while, the
distribution and number of histaminergic cell bodies remained
similar to that of normal brains (Airaksinen et al., 1991). Braak
et al. (1993) suggested that during the course of AD, diminished
histamine production is paralleled by build up of NFT in the
TMN in the early stages. In agreement with this, a significant
loss of large-sized histamine containing neurons in the rostral
TMN was observed where numerous NFT were found, indica-
tive of a central histaminergic dysfunction (Nakamura et al.,
1993). Similarly, high performance liquid chromatography results
in some studies have shown reduction in histamine content in the
hypothalamus, hippocampus, and temporal cortex of AD brains
(Mazurkiewicz-Kwilecki and Nsonwah, 1989; Panula et al., 1998).
But clearly, the number studies that evidenced a decline in his-
tamine level is more than the studies that observed an excess of
brain histamine in AD. These discrepancies may have arisen from
the putative confounding factors like post-mortem delays and dif-
ferences in subjects assessed e.g., control subjects from a different
population than AD patients (Panula et al., 1998).
Central histaminergic fibres originating from the TMN in
the posterior hypothalamus (Brown et al., 2001) widely projects
into different brain areas including the cerebral cortex, thala-
mus, basal ganglia, amygdala, and hippocampus, where histamine
is crucially associated with a large number of basic physiologi-
cal functions including sensory and motor functions, cognition,
attention, learning, and memory (Haas et al., 2008). Blockade of
human H3 autoreceptor by thioperamide evokes the increase of
the neuronal histamine release (Flik et al., 2011), and the neu-
rotransmitter modulates cognition processes via both human H1
and H2 receptors or via cholinergic and GABAergic interneurons
either directly via excitation of neocortical pyramidal neurons
and thalamic relay neurons or indirectly via excitation of ascend-
ing cholinergic neurons (Bacciottini et al., 2001; Haas and Panula,
2003; Haas et al., 2008). The H3R heterogeneity was revealed
in a microdialysis study, where local TMN administration of
H3R antagonist yielded variable histamine release in different
brain areas: whereas the concentration increased in TMN, nucleus
basalis magnocellularis (NBM), and prefrontal cortex (PFC), it
remained unchanged in striatum and nucleus accumbens (NAc).
There was differential regulation of neurotransmitter release in
a region-specific manner in the brain (Giannoni et al., 2010).
The degeneration of histamine neurons in AD does not paral-
lel with the extent of H3R expression. In fact, only a very minor
portion of brain H3Rs are located in histaminergic neurons and
are largely expressed in deep cortical and thalamocortical projec-
tion neurons and in striatal neurons among many other neuron
populations. Thus, despite a strong AD related neurodegener-
ation of the TMN in its severe late stages, H3R densities are
either preserved in the brains of amyloid overexpressing TASTPM
transgenic mice as well as of AD patients as revealed by receptor
binding data (Medhurst et al., 2007, 2009) or increased expression
of H3R mRNA (in brains of female AD patients) is evidenced by
PCR studies (Shan et al., 2012), signifying that they constitute an
adequate target to improve the cognitive disorders encountered
in AD.
Recently H3R ligands are being extensively investigated
for their potential as a therapeutic agent for cognitive deficits
(Sander et al., 2008; Tiligada et al., 2009; Brioni et al., 2011; Leurs
et al., 2011). In preclinical studies, H3R antagonists enhance
histamine neuron activity and a simultaneous improvement
in cognition and learning was observed (Passani et al., 2004).
Clearly, the promising preclinical findings have given strong
impetus for numerous pharmaceutical companies to embark
on proof-of-concept clinical studies with a number of H3
antagonists for diverse neurological conditions including AD
(Drahl, 2009; Abbott-press release, 2011; GSK-pipeline, 2011).
Recently phase II trials of H3R antagonists ABT-288 (NCT-ID
NCT01018875), GSK239512 (NCT-ID NCT01009255), and
MK0249 (NCT-ID NCT00420420) for mild to moderate AD
have been completed. The outcomes of these trials have not
yet been publicly divulged. Another compound PF-03654746
has completed phase I clinical trial (NCT-ID NCT01028911)
to evaluate its safety, tolerability and blood levels in mild
to moderate AD patients and is subjected to phase II trial
(http://www.pfizer.com/files/research/pipeline/2010_0927/pipeli
ne _2010_ 0927.pdf).
Degeneration of the basal forebrain cholinergic neurons
occurs early in the course of AD and has been correlated well
with the observed cognitive decline in such patients (Coyle et al.,
1983). Reduced acetylcholine (ACh) levels and function in the
brain is considered to be the classical attribute to cognitive deficits
in AD. Researchers have found that besides controlling histamine
release, H3R antagonists may alleviate AD associated cognitive
deficits by augmenting release of other neurotransmitters includ-
ing ACh (Passani et al., 2004; Haas et al., 2008). H3R antagonists
enhanced ACh levels in the PFC and in the dorsal hippocam-
pus accompanied by an improvement of cognitive functions in
behavioral studies in rodents (Fox et al., 2005). However, the
progressive cholinergic cell loss in basal forebrain linked with
AD (Whitehouse et al., 1982) probably confines the therapeu-
tic efficacy of drugs to be reliant on endogenous ACh synthesis
and doesn’t provide disease-modifying efficacy in addition to
symptomatic improvement.
The two cardinal features of AD pathology speculated to be
the potential targets of disease-modifying drugs are β-amyloid
(Aβ), a product of aberrant amyloid precursor protein (APP)
leading to production of extracellular Aβ plaques, and NFT aris-
ing from hyperphosphorylation of tau, a microtubule-associated
protein (Giacobini and Becker, 2007). Activation of cellular path-
ways that inhibit tau kinase signaling and subsequent tau hyper-
phosphorylation is considered to be the most feasible strategy
to prevent tau aggregation and associated pathological effects.
Suppression of tau protein can also block Aβ-induced apop-
tosis thereby reducing cognitive deficits (Martin et al., 2011).
A recent study using rat PC12 tumour cell line demonstrated
neuroprotective effects of clobenpropit, an H3R antagonist, on
injury produced by Aβ42 toxicity (Fu et al., 2010). Though
there are several mechanisms that are thought to be involved in
Aβ toxicity, a glutamate mediated mechanism was suggested in
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this study. An encouraging preclinical evidence with the H3R
antagonist ABT-239 suggests that H3R antagonism might not
only deliver symptomatic treatment in AD, but also possess
disease-modifying benefits (Bitner et al., 2011). Acute adminis-
tration of the H3R antagonist ABT-239 in CD1 mice increased
cortical CREB (cAMP response element binding protein) and
Ser9-GSK-3β phosphorylation (GSK-3β phosphorylated at ser-
ine 9) at cognitive enhancing doses. Furthermore, donepezil (an
acetylcholinesterase inhibitor) at clinical doses induced CREB
phosphorylation consistent with a pro-cognitive action, but
unlike ABT-239, did not alter Ser9-GSK3β level (Bitner et al.,
2011). Together, these findings indicated that increased Ser9-
GSK3β phosphorylation induced by ABT-239 is independent of
increased ACh release. In an earlier study by the same group, both
CREB and Ser9-GSK3β phosphorylation were shown to be down-
regulated in the Tg2576 (APP/Aβ) transgenic mousemodel of AD
(Bitner et al., 2009). However, a 2-week infusion of ABT-239 in
Tg2576 mice restored reduced cortical CREB and hippocampal
pSer9-GSK3β phosphorylation. In parallel studies conducted in
female TAPP mice, an AD transgenic line expressing both APP
and tau transgenes, ABT-239 infusion reversed tau hyperphos-
phorylation in the spinal cord and hippocampus (Bitner et al.,
2011). Mechanistically, ABT-239 produced pSer9-GSK3β changes
in α7 nicotinic ACh receptor (nAChR) knockout mice, an effect
also observed in normal mice that exhibit α7 nAChR agonist-
induced phosphorylation (Bitner et al., 2009), suggesting that
H3R antagonist-mediated signaling (increased pSer9-GSK3β)
does not appear to require ACh-stimulated α7 nAChR activation
(Bitner et al., 2011). These in vivo signaling studies boost the
exciting prospect that H3R antagonists activate multiple signal-
ing pathways that may translate into improved disease-modifying
efficacy in patients with AD, along with symptomatic alleviation
(Bitner et al., 2011; Brioni et al., 2011). Thus, it can be hypothe-
sized that H3R antagonist-evoked neurotransmitter release (e.g.,
ACh) leads to activation of postsynaptic receptor pathways such
as phosphorylation-activation of CREB, a transcription factor rel-
evant to cognitive function, and phosphorylation of inhibitory
residue Ser9 of GSK3β, a primary tau kinase in AD responsi-
ble for tau hyperphosphorylation (Hooper et al., 2008; Bitner
et al., 2011). This, together with the disease-modifying capac-
ity of H3R antagonist might also impact the underlying disease
pathology (e.g., tau phosphorylation) beyond mere symptomatic
alleviation (reviewed by Brioni et al., 2011). In line with the above
view, Abbott has suggested a combinatorial treatment of cognitive
disorders consisting of a nAChR ligand (either α4β2 or α7 sub-
type) and a H3R antagonist e.g., ABT-239 (Abbott laboratories,
WO2009082698; 2009) which can also include psychostimulants
(e.g., methylphenidate) or monoamine re-uptake inhibitors (e.g.,
atomoxetine) to achieve greater clinical efficacy (Lazewska and
Kiec-Kononowicz, 2010).
ATTENTION-DEFICIT HYPERACTIVITY DISORDER
ADHD is a disorder most prevalent in children characterized by
persistent carelessness, hyperactivity, and impulsivity. The cur-
rent pharmacological treatments of ADHD include stimulants
(methylphenidate, amphetamines, etc.), non-stimulant (atomox-
etine), α2 agonists (clonidine and guanfacine) etc. However, these
treatments (mainly stimulants) are associated with significant
adverse effects and abuse liability. The potential usefulness of H3R
antagonists in this pathology is buttressed by their pro-attentional
and pro-cognitive activity in a number of rodent models [such
as object recognition task, social recognition task, spontaneous
hypertensive rats (SHR), and five-choice stimulus reaction time
test (5-CSRTT)] which is devoid of any psychomotor activa-
tion and abuse liability (Gemkow et al., 2009; Kuhne et al.,
2011; Passani and Blandina, 2011). ADHD involves interplay of
multiple neurotransmitter systems mainly of dopaminergic and
noradrenergic systems but also of cholinergic and serotonergic
systems (Curatolo et al., 2009; Cortese, 2012). While stimulants
block the reuptake of dopamine (DA) and norepinephrine (NE)
into presynaptic neuron (amphetamine in addition also promotes
release), atomoxetine, a non-stimulant drug, blocks NE trans-
porter thereby increasing concentrations of NE throughout the
brain but DA only in PFC (Cortese, 2012). In agreement, H3R
antagonists have been shown to elevate the release of neurotrans-
mitters involved in cognition e.g., ACh and DA in the PFC (Fox
et al., 2005; Ligneau et al., 2007), ACh, DA, and NE in the anterior
cingulate cortex (Medhurst et al., 2007; Southam et al., 2009), and
AChh in the hippocampus (Fox et al., 2005).
In preclinical models, pharmacological alterations that antag-
onize the cholinergic system or enhance the various neurotrans-
mitter systems like DA, orexin, cannabinoids systems including
histamine cause hyperactivity [an increase in locomotor activity
(LA)] that accompanies various neurological disorders including
ADHDThe LA can be decreased by genetic alterations that reduce
the level of histamine (e.g., in HDC KO mice) or by lesions of
the TMN (Viggiano, 2008). Recently, H3R antagonist (carnicine,
a stable analog of the naturally occurring dipeptide carnosine)
attenuated hyperlocomotion in an ADHD-specific model with
neonatal habenula lesion without having an effect on attention-
deficit (Goto and Lee, 2011). In other studies, antagonists of H3R
have demonstrated pro-attentional effects in various ADHD-
specific animal models including five-trial inhibitory avoidance
in SHR pups (thioperamide, ABT-239, GT-2331, and ciproxifan)
(Fox et al., 2002; Komater et al., 2003) and impairment in a 5-
CSRTT (ciproxifan) (Day et al., 2007). In addition, CEP-26401
(irdabisant), antagonized H3R agonist R-α-methylhistamine-
induced drinking response in the rat dipsogenia model, improved
performance in the rat social recognition model of short-term
memory, and showed wake-promoting properties (Raddatz et al.,
2012). Recently, a single-blind trial with pitolisant (BF2.649) in 28
adult ADHD patients yielded a progressive improvement in clini-
cal scores. However, the placebo also showed some effect in this
trial, so the clinical efficacy is unclear which merits confirma-
tion in a double-blind trial in adults and children (Schwartz,
2011). In addition, MK-0249 (NCT-ID NCT00475735) has com-
pleted phase II clinical trials for ADHD but the results are still
awaited in public domain (Brioni et al., 2011; Kuhne et al., 2011).
PF-03654746 recently completed a phase II trial (NCT00531752)
in adult ADHD patients, though no efficacy was observed vs.
placebo (Brioni et al., 2011). Likewise, in a randomized clinical
study, ADHD-RS-IV score (primary efficacy end point of ADHD)
of bavisant, a highly selective, wakefulness-promotingH3R antag-
onist, though displayed an improved trend, was not statistically
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significant compared with placebo in ADHD patients (Weisler
et al., 2012). These data accumulating from rodent models and
clinical settings underpin the idea that modulation of H3R rep-
resents a novel therapeutic target for the treatment of ADHD
especially due to its wider therapeutic role in CNS and the fact
that ADHD is frequently co-morbid with sleep disorders, learn-
ing difficulties, substance abuse, anxiety, depression and other
neuropsychiatric disorders (Cortese, 2012).
In addition to impairedmotor functions and vigilance, ADHD
is also associated with impairment of cognitive functions (Bidwell
et al., 2011) even though the direct clinical relevance of interven-
tions enhancing cognitive functions in the treatment of ADHD
appears limited. Nevertheless, several classes of anti-ADHD drugs
have uniformly shown evidence of acute cognitive enhancement
and improvement in the core symptoms of ADHD. As described
in AD section, a wide array of neurobiological mechanisms
have been attributed for the observed pro-cognitive and pro-
attentional effects of H3R antagonists in rodent models includ-
ing H3R antagonists mediated enhancement of neurotransmitter
release (Passani et al., 2004; Giannoni et al., 2010) or modula-
tion of electrophysiological activity (Hajos et al., 2008; Andersson
et al., 2010) in the hippocampus, induction of immediate early
gene expression in brain regions, such as the NAc (Southam et al.,
2009) or motor cortex (Bonaventure et al., 2007), that directly
regulates locomotor behavior; disruption of dopaminergic activ-
ity related to hyperactivity induced by DA agonists, such as
apomorphine, cocaine, and methamphetamine (Fox et al., 2005;
Ligneau et al., 2007) although paradoxes (Ferrada et al., 2008;
Brabant et al., 2009) have also been reported. Recently ciproxifan,
H3R antagonist, alleviated hyperactivity and memory impair-
ment in an amyloid-precursor protein transgenic (APPTg2576)
mouse model of AD (Bardgett et al., 2011). APP (Tg2576) mice
displayed significantly increased LA and longer escape latencies in
the swim maze than wild-type mice. In probe trials, ciproxifan-
treated APP (Tg2576) mice spent more time near and made more
crossings of the previous platform location than did saline-treated
APP (Tg2576) mice. Acute ciproxifan treatment also reversed
impaired object recognition task in APP (Tg2576) mice (Bardgett
et al., 2011). It was hypothesized that the loss of synapses in the
hippocampus of APPTg2576 mice possibly caused dysregulation
in the NAc and H3R antagonist via increased neurotransmit-
ter release in the hippocampus or by induction of early gene
expression in NAc or motor cortex regulated LA.
SCHIZOPHRENIA
Schizophrenia, a chronic debilitating neurological syndrome
with 0.5–1% prevalence worldwide, is characterized by posi-
tive (e.g., hallucination and delusion), negative (e.g., paucity
of emotion and motivation), and impaired cognitive symp-
toms. Though basic knowledge at the level of molecular etiol-
ogy and psychopathology is inadequate to delineate molecular
targets for drug development, dysregulation in DA and other
neurotransmitter systems are involved in the development of
the disease (Gross and Huber, 2008). Current pharmacotherapy
for schizophrenia consists of first generation (FGA) and sec-
ond generation (SGA) antipsychotics, which mainly act by DA
antagonism in CNS mediated mainly by DA D2- receptors but
also by D3R and/or D4R, serotonin receptor (5-HTR) subtypes
(5-HT2AR/5-HT2CR) and/or via modulation of the glutamater-
gic system (Sander et al., 2008) which may evoke extrapyramidal
(mainly FGAs) and/or serious metabolic disorders (Deng et al.,
2010). Due to several adverse effects of antipsychotic therapy,
rising therapeutic resistance and inadequate treatment of nega-
tive symptoms, H3R antagonist could be a pervasive therapeutic
strategy owing to its pro-cognitive property (Ito, 2009).
Histaminergic innervations into the brain areas closely associ-
ated with the development of schizophrenia raises the possibility
of H3R antagonists influencing its pathophysiology. The clini-
cal relevance of H3R in schizophrenia is bolstered by their high
density presence, mostly postsynaptically, in the GABAergic stri-
atal efferent neurons. There they are co-localized with DA D1
and D2 receptors and form heterodimers with the D1 recep-
tor in GABAergic dynorphinergic and with the D2 receptor on
GABAergic enkephalinergic neurons, respectively (Pillot et al.,
2002a; Ferrada et al., 2008). This intracellular cross-talk results
in modified signaling directed by the heterodimer which may
underlie the pathogenesis of schizophrenia: e.g., H3-D1 recep-
tor heteromer induces a Gi protein mediated activation of MAPK
pathway (Ferrada et al., 2009) whereas H3-D1/D2 heteromers
exhibited an antagonistic interaction as H3R agonism negatively
modulated D1 or D2 receptor function (Ferrada et al., 2008). H3R
antagonists are anticipated to mediate their action by exploit-
ing these functional cross-talks. Ciproxifan, an H3R antagonist,
potentiated locomotor hypoactivity and catalepsy induced by
haloperidol, a widely used antipsychotic, via enhanced activa-
tion of striatopallidal neurons of the indirect movement pathway,
upregulation of proneurotensin, proenkephalin, and c-fos (Pillot
et al., 2002b). Though ciproxifan potentiated haloperidol induced
catalepsy, it had no effect on catalepsy when administered alone
implicating that no extrapyramidal side effect would result from
their therapeutic use when used alone. The same team, a year
later, revealed that ciproxifan suppressed the methamphetamine-
induced upregulation of striatal neuropeptides like prodynorphin
and substance P, the D1-receptor-mediated responses; attenuated
methamphetamine induced locomotor hyperactivity possibly by
inhibition of striatonigral neurons in NAc involved in regu-
lation of locomotor function (Pillot et al., 2003). Thus H3R
cross-talk with dopaminergic receptor system has opened a new
avenue for designing anti-schizophrenics. Further, BF2.649 acti-
vated DA turnover in the PFC but not in striatum, thus possessing
a favorable profile similar to SGAs with low liability to induce
extrapyramidal symptoms (Ligneau et al., 2007).
As a proof of concept, numerous data has accumulated from
schizophrenia cases studied in both rodent models and in human
subjects: increased H3R radioligand binding was found in dorso-
lateral PFC of schizophrenic subjects and bipolar subjects with
psychotic symptoms (Jin et al., 2009) and antipsychotic-like
profile of H3R antagonists observed in animal models. The lat-
ter included improvement of prepulse inhibition (PPI) deficits
in rodent schizophrenia models by H3R antagonists/antagonists
such as ABT-239 in DBA/2 mice (Fox et al., 2005), pitolisant
in Swiss mice (Ligneau et al., 2007), GSK-189254 in Wistar rats
(Medhurst et al., 2007), and more recently irdabisant in rats
(Raddatz et al., 2012). In DBA/2NCrl mice, CEP-26401 increased
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PPI of the acoustic startle response alone and also showed syn-
ergistic effect when co-administered with risperidone at subeffi-
cacious doses (Raddatz et al., 2012). The PPI deficits model the
impairment of sensorimotor gating in acoustic startle response
in schizophrenic patients. Stimulation of DA activity is criti-
cal for attenuation of such deficits induced by amphetamines
and other DA agonists and NMDA antagonists. In addition
to PPI, antagonism of dopaminergic stimulants (amphetamine,
apomorrphine)-induced hyperactivity is important mechanism
in pathophysiology of diseases associated with hyperactivity of
dopaminergic pathway including schizophrenia and drug abuse.
Animal studies demonstrated an antagonism of amphetamine
and MK-801 (NMDA R antagonist)-induced motor activation
by BF2.649 in mice (Clapham and Kilpatrick, 1994; Ligneau
et al., 2007) and attenuation of amphetamine, methamphetamine
and apomorphine-induced locomotor stimulation and/or stereo-
typy by thioperamide and ciproxifan (Clapham and Kilpatrick,
1994; Morisset et al., 2002) in rodent models. While acute
amphetamine induced locomotor stimulation is known to repre-
sent the euphoric and abusive effects rather than psychosis which
is mainly modeled by chronic amphetamine induced locomo-
tor sensitization models (Trujillo et al., 2004), H3R antagonist
ciproxifan also reduced LA inmethamphetamine induced chronic
sensitization model (Motawaj and Arrang, 2011).
Contrary to these, reports ranging from partial or no sup-
pression of apomorphine induced stereotypies (Burban et al.,
2010) and no improvement in sensorimotor gating deficits in rats
(Southam et al., 2009; Burban et al., 2010) by H3R anatgonists to
even exacerbation of hyperactivity (Ferrada et al., 2008; Burban
et al., 2010) has also been documented. Cross-talk between H3R
and D1/D2 receptor (Ferrada et al., 2008; Burban et al., 2010);
interaction between the severity of endpoints (startle magnitude
and changes in PPI) used in experimental paradigm that modeled
schizophrenia, different levels of PPI among different species and
strains (Burban et al., 2010), H3R antagonist used, route adminis-
tered, specific memory task studied may partially account for the
discrepancies (Bardgett et al., 2009) are some of the confounding
factors which needs to be taken into account.
Cognitive impairment, a hallmark trait of schizophrenia, is the
central determinant of functional outcomes associated with this
disease. Although current antipsychotic drugs, mainly targeting
the positive psychotic symptoms of the illness, treat psychosis in
schizophrenia rather well, their impact on cognitive dysfunction
is minimal or largely untreated. In recent years there has been
growing interest in developing novel treatments for cognitive
deficits in schizophrenia (Ibrahim and Tamminga, 2012). H3R
antagonists increased hippocampal gamma (Andersson et al.,
2010) and theta oscillation power (Hajos et al., 2008). Deficits of
cognition-relevant neuronal oscillations are observed in individ-
uals with schizophrenia which would result in erroneous higher-
order cognitive processes, including sensory perception, coherent
feature binding, attention, memory, and object representation,
that manifest as the positive and negative symptoms of the disease
(Shin et al., 2011). Augmentation of DA release in the PFC is key
to minimize the negative symptoms and cognitive impairment
elicited by antipsychotics. H3R antagonists, enjoy the advantage
of enhancing DA release from PFC (Fox et al., 2005; Ligneau et al.,
2007; Medhurst et al., 2007), thus may have a sparing effect on
prefrontal function over strong DA antagonizing antipsychotics.
Although, inconsistent findings on animal models mimick-
ing schizophrenia does not bring any full proof evidence for
antipsychotic properties of H3R antagonists, their waking and
pro-cognitive properties uphold their therapeutic interest and
can be exploited to adequately address the cognitive impairment
central to schizophrenic patients which is resistant to current neu-
roleptics in hand, hence better clinical outcome. A recent study
on ciproxyfan in mice showed a reversal of methamphetamine-
induced LA, reversal of downregulation of brain-derived neu-
rotrophic factor (BDNF) and NMDA receptor subunit 1 genes
in various regions of mice brain, reinforcing the interest of H3R
antagonists in the treatment of cognitive deficits in psychotic
patients (Motawaj and Arrang, 2011). Further, the results of
clinical studies undertaken by numerous pharmaceutical compa-
nies are now eagerly awaited to establish the proof of concept.
Pitolisant has completed Phase II of clinical trials showing effi-
cacy in patients suffering from antipsychotic-induced weight gain
and hence might be useful for co-treatment (WO2006084833A1).
A study designed to assess the pro-cognitive potential of tipro-
lisant in people with schizophrenia and schizoaffective disorder
is currently underway (NCT-ID NCT00690274). A Phase I trial
of PF-03654746 as an add-on treatment of cognitive deficits in
schizophrenic patients has been completed [87] without pub-
licly disclosed results. H3R antagonists ABT-288, GSK-239512,
and MK0249 have recently completed Phase II trials for cog-
nitive impairments in schizophrenia (NCT-ID NCT01077700,
NCT01009060, and NCT00506077) although the outcomes of
these studies remain undisclosed so far. The findings of ongoing
clinical trials in this area will be invaluable in guiding the future
course of action.
ADDICTION
Addiction is a persistent, compulsive dependence on a behavior
or substance. One common mechanism for addiction caused by
various drugs of abuse is thought to be the activation of brain’s
reward circuitry which mainly involves mesolimbic dopaminergic
neurons in the ventral tegmental area (VTA) of the midbrain and
their targets in limbic forebrain especially NAc (Nestler, 2005).
However, other neurotransmitter systems including histamine are
known to modulate the psychotropic effects of rewarding drugs
[role of histamine reviewed recently by Brabant et al. (2010)]. The
fact that histamine also modulates mesolimbic DA transmission
suggests that histaminergic drugs may be tried therapeutically in
drug addiction (Munzar et al., 2004; Brabant et al., 2010). Though
NAc, themain region involved in addiction, receive only weak his-
taminergic innervations, very high densities of H3Rs are present
here. Striatum contains one of the highest densities of H3Rs in
the brain (Pollard et al., 1993; Pillot et al., 2002a). Mainly, stri-
atal H3Rs are located postsynaptically in the GABAergic efferent
neurons where they are co-localized with D1 and D2 recep-
tors (Ferrada et al., 2008). They are also located presynaptically
on dopaminergic terminals in the striatum where they have an
inhibitory role on DA release. The central administration of his-
tamine is known to produce a biphasic effect on LA, initially a
brief reduction (hypoactivity) followed by a prolonged increase
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in LA (hyperactivity) (Bristow and Bennett, 1988). The initial
hypoactivity is presumed to be due to stimulation of presy-
naptic H3Rs (heteroreceptors) reducing DA activity and release
(Chiavegatto et al., 1998). Thus, histamine is known to have an
inhibitory effect on reward by inhibition of mesolimbic dopamin-
ergic system. Histamine can also activate mesolimbic dopaminer-
gic system possibly via presynaptic H3Rs located on DA terminals
or postsynaptically on GABAergic neurons in striatum or through
H1 Rs located on striatal cholinergic interneurons (reviewed by
Brabant et al., 2010). Activation of H3Rs that were found to
form heteromers with D2 Rs on GABAergic neurons attenu-
ated stimulant (quinpirole)-induced hyperactivity (Ferrada et al.,
2008).
Addictive drugsmodulate the histamine levels in the brain. For
instance, alcohol affects histamine levels in the brain by modu-
lating histamine synthesis, release and turnover (Zimatkin and
Anichtchik, 1999), acute injection of cocaine increases histamine
levels and histamine-N-methyl transferase activity in the striatum
and NAc (Ito et al., 1997) and opioids (e.g., morphine) increases
turnover of neuronal histamine via opioid receptors (Nishibori
et al., 1985). On the other hand, histaminergic system can modu-
late behavioral effects of various drugs of abuse including cocaine,
amphetamines, opioids, and alcohol. All addictive drugs stimulate
LA (psychomotor stimulant effects). Several studies demonstrate
that H1-antagonists produce behavioral and/or neurochemical
effect similar to addictive drugs possibly by blocking DA uptake
thereby facilitating the activity of mesolimbic dopaminergic sys-
tem (Brabant et al., 2010; Levin et al., 2011). However, a phar-
macokinetic interaction between H1-antagonists (inhibition of
CYTP450 CYP2D enzymes) and methamphetamine leading to
elevated levels of the latter (Okuda et al., 2004) could not be ruled
out. Locomotion activation by amphetamine/methamphetamine
and other dopaminergic agonists was attenuated by H3R block-
ade by thioperamide (Clapham and Kilpatrick, 1994), ciproxifan
(Motawaj and Arrang, 2011), ABT-239 (Fox et al., 2005), or
BF2.649 (Ligneau et al., 2007) in rodents in acute and chronic
behavioral sensitization models. The latter is repeated adminis-
tration of drug leading to an augmentation of behavioral effects
of psychostimulants on re-administration (Celik et al., 2006).
However, evidence contradicting the same is also available. For
instance, there are cases where H3R antagonists (GSK-207040,
Southam et al., 2009 and JNJ-5207852, JNJ-10181457, Komater
et al., 2003) did not reverse amphetamine-induced hyperactiv-
ity or H3R antagonist thioperamide increased cocaine-induced
hyperlocomotion in mice (Brabant et al., 2010). Indeed, the
potentiating effects of imidazole-based H3R antagonists like thi-
operamide, clobenpropit on stimulants could also be due to
their inhibitory effects on cytochrome P450 activity as the non-
imidazole based antagonist doesn’t enhance cocaine-induced
stimulant effects (Brabant et al., 2009). Repeated administration
of methamphetamine increases HDC activity in striatum and cor-
tex in rats (Ito et al., 1996) and release of histamine in mice
(Dai et al., 2004). Consistently, antagonism of H3Rs increases
methamphetamine-induced stereotypic hyperactivity in young
male mice (Acevedo and Raber, 2011), an effect contradicting the
so-called antipsychotic profile of H3R antagonists. There are also
reports where thioperamide potentiated the locomotor activation
induced by D1 or D2R agonist (Ferrada et al., 2008) suggesting an
antagonistic interaction between postsynaptic H3 and D1 or D2
receptors.
Self-administration and conditioned place preference (CPP)
paradigms are widely employed to study reinforcing or reward-
ing effects of drugs of abuse. Histamine has a negative effect
on reinforcement because H1-antagonists can act as reinforcers
either alone or with other reinforcers like opiates, cocaine, or
amphetamine (Brown et al., 2001). Going by this hypothesis,
H3R antagonists should prevent reinforcement. Indeed, H3R
antagonists (ciproxifan and JNJ-10181457) were found to inhibit
the ethanol-evoked CPP whereas H3R agonist immepip did not
alter ethanol-induced place preference in male DBA/2J mice.
This is further supported by a study where H3 R knock-out
(H3RKO) mice did not develop alcohol-induced CPP (Nuutinen
et al., 2011). Inhibition of ethanol reward by H3R antagonism
implies that H3R might be a noble target to suppress compul-
sory ethanol seeking (Nuutinen et al., 2011). H3R antagonists
also reduced the ethanol drinking in alcohol-preferring (AA)
rats (Lintunen et al., 2001; Galici et al., 2011) and blocked
rewarding and reinforcing effects of ethanol in DBA/2 mice
(Nuutinen et al., 2011). However, they increased acute stimu-
latory effects of ethanol. The same authors also reported that
ciproxifan increased ethanol CPP in mice (Nuutinen et al.,
2010) but reduced ethanol-induced locomotor activation in
C57BL/6 mice. Consistent to this, thioperamide and clobenpro-
pit increased methamphetamine self-administration and reward
possibly through H3 heteroreceptors located on dopaminergic
terminals increasing DA release in VTA (Munzar et al., 2004).
H3R antagonists also increased cocaine CPP (Brabant et al., 2005)
but suppressed LA induced by amphetamine.
Repeated exposure to cocaine, amphetamine or opiates
induces phosphorylation and activation of CREB in several
reward-related brain regions including NAc whereas alcohol
and nicotine reduces CREB phosphorylation in this region. In
NAc, psychostimulants induce CREB via activation of DA D1
receptors (Goodman, 2008). Acute administration of ABT239
increased cortical CREB while its continuous infusion normal-
ized reduced cortical CREB phosphorylation in AD transgenic
mice (Bitner et al., 2011). In another study, sensitization by
methamphetamine-induced reduction of BDNF mRNA in the
hippocampus and NMDA R subunit 1 (NR1) mRNA in cerebral
cortex, hippocampus and striatum, was reversed by ciproxifan
(Motawaj and Arrang, 2011). The effects of H3R antagonists have
not been mechanistically evaluated for their effects on CREB
phosphorylation or BDNF in brain regions relevant for drug
abuse.
CONCLUSION
Cognitive dysfunction and motor impairments are the hallmark
of multifarious neurodegenerative and/or psychiatric disorders
including AD, ADHD, schizophrenia, and drug abuse. The neu-
rochemical basis interlinking these complex behavioral traits in
these diseases conditions is complex and it is unclear whether they
derive from alterations in a common neuronal circuit. H3R antag-
onists/inverse agonists, through H3 heteroreceptors, enhance the
release of various important central neurotransmitters in brain
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in addition to histamine and hence can modulate various pro-
cesses of the CNS including cognition. In addition, postsynaptic
H3Rs are present in striatum at GABAergic cell bodies of the
medium spiny neurons both on the striatonigral neurons of the
direct movement pathway and on the striatopallidal neurons
of the indirect movement pathway modulating motor activity
(Nuutinen et al., 2011). Locomotor hyperactivity accompanies
not only ADHD but also AD and schizophrenia (Viggiano,
2008). Likewise, attentional impairments are observed not only
in ADHD but also in Schizophrenia, AD, and drug abuse. It
is noticeable that the latter accompanies cognitive and atten-
tional deficits too (Potenza et al., 2011). Such deficits observed
in chronic alcohol, cocaine, and methamphetamine abusers is
considered to be a particular challenge for treatment-seeking
users who require intact cognitive functioning to stop drug
abuse. Thus, various cognition enhancing strategies and anti-
ADHD drugs have been tried in drug abuse, e.g., atomoxetine,
a selective norepinephrine transporter (NET) inhibitor. Similarly,
cognitive enhancers are useful in improving attention in ADHD
(Bidwell et al., 2011; Levin et al., 2011). Histamine H3R antag-
onists, though not directly linked to the pathophysiology of
disease states, improve cognitive functions and increase alertness,
wakefulness, learning, memory without significantly impairing
motor functions and thus provides a rationale for their eval-
uation and research on various neurological conditions where
impairment of such functions is paramount especially AD, the
most common cause of progressive decline of cognitive func-
tions, and others including ADHD, schizophrenia, epilepsy, nar-
colepsy, and drug abuse. The broad spectrum of activities of
H3R antagonists continues to expand as more and more novel
therapeutic roles have been investigated including Parkinson’s
disease, multiple sclerosis, cerebral ischaemia, depression, etc.,
and hence identification of potential clinical targets. Nevertheless,
many issues such as paucity of clinical data and specific stud-
ies evaluating the molecular mechanisms involved in the role
of H3R antagonists as well as the conflicting nature of the
data gathered so far in pharmacological/biochemical evaluations,
remains a challenge that remains to be answered with more rig-
orous evaluations to develop H3R specific therapeutic agents for
human use.
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